New drug shows promise for kidney disease in early trial
NCT ID NCT06670352
First seen May 29, 2026 · Last updated Jun 12, 2026 · Updated 4 times
Summary
This study tested a new tablet called HSK39297 in 87 adults with IgA Nephropathy, a kidney disease. The goal was to see if it could reduce protein in the urine, a sign of kidney damage, compared to a placebo. The trial lasted 12 to 24 weeks and aimed to check both safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210000, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Conditions
Explore the condition pages connected to this study.